The Dow Jones Industrial Average (DJINDICES: ^DJI) fell sharply after the U.S. released a new tariff program. Does that open ...

Merck is in hot water after a class action lawsuit alleged securities fraud over its Gardasil revenue forecasts in China. The lawsuit claims Merck misled investors about its ability to achieve $11 ...

We recently published a list of 10 Defensive Stocks Billionaire Ken Fisher is Betting On. In this article, we are going to ...

Analysts have mixed feelings about Merck & Co., Inc., assigning it a “Moderate Buy” with an average price target of $117.12.

In a report released today, Tim Anderson from Bank of America Securities maintained a Buy rating on Merck & Company (MRK – Research ...

The Gross Law Firm issues the following notice to shareholders of Merck & Co., Inc. . Shareholders who purchased shares of MRK ...

Research analysts at Zacks Research lowered their Q4 2026 EPS estimates for shares of Merck & Co., Inc. in a report released ...

Research analysts at Zacks Research reduced their Q1 2026 EPS estimates for shares of Merck & Co., Inc. in a research note issued to investors on Tuesday, April 1st. Zacks Research analyst S. Ganoria ...

Potato producer Lamb Weston Holdings Inc., telecom giant Verizon Communications Inc. and retailer TJX Cos. all bucked a sharp market selloff Thursday, as Wall Street turned to stocks offering exposure ...

ImmunityBio, Inc.'s advances with Anktiva & rBCG show promise amid financial hurdles. Click here to find out why IBRX stock ...

TD Cowen analyst Steve Scala maintained a Hold rating on Merck & Company (MRK – Research Report) today and set a price target of $100.00.

Merck & Co. Inc. closed 33.72% short of its 52-week high of $134.63, which the company achieved on June 25th.